Literature DB >> 19036881

Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.

Feng Fang1, Michael A Rycyzyn, Charles V Clevenger.   

Abstract

Implicated in the pathogenesis of breast cancer, prolactin (PRL) mediates its function in part through the prolactin receptor (PRLr)-associated Janus kinase 2 (Jak2)/signal transducer and activator of transcription 5 (Stat5) signaling complex. To delineate the mechanisms of Stat5a regulation in breast cancer, transcription factor-transcription factor (TF-TF) array analysis was employed to identify associated transcriptional regulators. These analyses revealed a PRL-inducible association of Stat5a with the transcription factor and protooncogene c-Myb. Confirmatory co-immunoprecipitation studies using lysates from both T47D and MCF7 breast cancer cells revealed a PRL-inducible association between these transcription factors. Ectopic expression of c-Myb enhanced the PRL-induced expression from both composite and synthetic Stat5a-responsive luciferase reporters. Chromatin immunoprecipitation assays also revealed a PRL-inducible association between c-Myb and endogenous Stat5a-responsive CISH promoter, which was associated with an enhanced expression of CISH gene product at the RNA and protein levels. Small interfering RNA-mediated c-Myb knockdown impaired the PRL-induced mRNA expression of five Stat5-responsive genes. DNA binding-defective mutants of c-Myb, incapable of activating expression from a c-Myb-responsive reporter, maintained their ability to enhance a Stat5a-responsive reporter. At a cellular level, ectopic expression of c-Myb resulted in an increase in T47D proliferation. Taken together, these results indicate that c-Myb potentiates Stat5a-driven gene expression, possibly functioning as a Stat5a coactivator, in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036881      PMCID: PMC2659289          DOI: 10.1210/en.2008-1079

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  71 in total

1.  PRL activates the cyclin D1 promoter via the Jak2/Stat pathway.

Authors:  Jennifer L Brockman; Matthew D Schroeder; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2002-04

2.  Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Authors:  Idoya Lahortiga; Kim De Keersmaecker; Pieter Van Vlierberghe; Carlos Graux; Barbara Cauwelier; Frederic Lambert; Nicole Mentens; H Berna Beverloo; Rob Pieters; Frank Speleman; Maria D Odero; Marijke Bauters; Guy Froyen; Peter Marynen; Peter Vandenberghe; Iwona Wlodarska; Jules P P Meijerink; Jan Cools
Journal:  Nat Genet       Date:  2007-04-15       Impact factor: 38.330

Review 3.  Roles of unphosphorylated STATs in signaling.

Authors:  Jinbo Yang; George R Stark
Journal:  Cell Res       Date:  2008-04       Impact factor: 25.617

4.  Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells.

Authors:  Ahmed S Sultan; Jianwu Xie; Matthew J LeBaron; Erica L Ealley; Marja T Nevalainen; Hallgeir Rui
Journal:  Oncogene       Date:  2005-01-27       Impact factor: 9.867

5.  Mechanism of c-Myb-C/EBP beta cooperation from separated sites on a promoter.

Authors:  Tahir H Tahirov; Ko Sato; Emi Ichikawa-Iwata; Motoko Sasaki; Taiko Inoue-Bungo; Masaaki Shiina; Kazumi Kimura; Shioka Takata; Atsushi Fujikawa; Hisayuki Morii; Takashi Kumasaka; Masaki Yamamoto; Shunsuke Ishii; Kazuhiro Ogata
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

6.  Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells.

Authors:  R Nanbu-Wakao; Y Fujitani; Y Masuho; M Muramatu; H Wakao
Journal:  Mol Endocrinol       Date:  2000-02

7.  Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells.

Authors:  María Aurora Domínguez-Cáceres; José Manuel García-Martínez; Annarica Calcabrini; Lorena González; Pedro González Porque; Javier León; Jorge Martín-Pérez
Journal:  Oncogene       Date:  2004-09-23       Impact factor: 9.867

8.  Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells.

Authors:  A R Buckley; D J Buckley; M A Leff; D S Hoover; N S Magnuson
Journal:  Endocrinology       Date:  1995-12       Impact factor: 4.736

9.  Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown.

Authors:  Tone Berge; Vilborg Matre; Elen M Brendeford; Thomas Saether; Bernhard Lüscher; Odd Stokke Gabrielsen
Journal:  Blood Cells Mol Dis       Date:  2007-06-22       Impact factor: 3.039

10.  Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells.

Authors:  Yvette Drabsch; Honor Hugo; Rui Zhang; Dennis H Dowhan; Yu Rebecca Miao; Alan M Gewirtz; Simon C Barry; Robert G Ramsay; Thomas J Gonda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-09       Impact factor: 11.205

View more
  18 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Authors:  Feng Fang; Jiamao Zheng; Traci L Galbaugh; Alyson A Fiorillo; Elizabeth E Hjort; Xianke Zeng; Charles V Clevenger
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

3.  HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Yi Liu; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-08-04

4.  MiR-15a suppresses hepatocarcinoma cell migration and invasion by directly targeting cMyb.

Authors:  Bo Liu; Ting Sun; Gang Wu; Hui Shang-Guan; Zhao-Jin Jiang; Ji-Ren Zhang; Yan-Fang Zheng
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

5.  Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.

Authors:  Jiamao Zheng; Feng Fang; Xianke Zeng; Terry R Medler; Alyson A Fiorillo; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-09-29

6.  The chicken miR-150 targets the avian orthologue of the functional zebrafish MYB 3'UTR target site.

Authors:  Audrey Guillon-Munos; Ginette Dambrine; Nicolas Richerioux; Damien Coupeau; Benoît Muylkens; Denis Rasschaert
Journal:  BMC Mol Biol       Date:  2010-09-02       Impact factor: 2.946

7.  MYB suppresses differentiation and apoptosis of human breast cancer cells.

Authors:  Yvette Drabsch; Ramsay G Robert; Thomas J Gonda
Journal:  Breast Cancer Res       Date:  2010-07-26       Impact factor: 6.466

8.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

9.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Authors:  Diane Gesty-Palmer; Ling Yuan; Bronwen Martin; William H Wood; Mi-Hye Lee; Michael G Janech; Lam C Tsoi; W Jim Zheng; Louis M Luttrell; Stuart Maudsley
Journal:  Mol Endocrinol       Date:  2013-01-11

10.  Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer.

Authors:  Alicia E Woock; Jacqueline M Grible; Amy L Olex; J Chuck Harrell; Patricija Zot; Michael Idowu; Charles V Clevenger
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.